ESR1 and breast neoplasm: Seventy percent of breast tumors express estrogen receptor alpha (ERα) implying eligibility for endocrine therapies including selective estrogen receptor modulators (SERMs), e. g., Tamoxifen (TAM), and aromatase inhibitors (AI), e. g., letrozole.